Company History - Strides Pharma Science
-Board approves for the allotment of 210,955 shares of the company at
Rs.10 each to the share holders of Bombay Drugs & Pharmas Ltd.
-Zenith Pharmaceuticals Ltd acquires 71% shares through preferential
-Board approves for the proposal of restructuring its Cram division
by hiving off into two separate company under the provisions of the
-Incorporates 'Strides Africa Ltd' at British Virgin Island with an
authorised capital of US $ 200,000 as 100% wholly owned subsidiary.
-Board decides to change the name of the company to 'Strides Arcolab
(FA)' to reflect the change in the business focus and operations.
-Nominates Mr Francis Pinto as the Director on the Board of the
-Forges an exclusive co-operation alliance with the South Africa
based drug manufacturer Aspen Pharmacare, mainly to share the product
development expertise and quality systems.
-Concludes the strategic development and manufacturing agreement with
Sorm Co. Ltd for long term supply of Generics, OTC and Nutraceutical
-Changes in the Management:
Appoints Mr V Hariharan as CFO, Mr Joe Thomas as President, and Mr
Krishna Kumar Menon as COO.
-Board approves for the reorganization of subsidiaries of the company
and for write off of dimunition in value of investments made in
subsidiaries by the company.
-Strides inks MoU with Ribbon SRL for Cephalosporin
-Major Fire occurs in Private Custom Bonded warehouse in Mexico
-Strides Arcolab Limited has entered into a memorandum of
understanding with BITS, Pilani for an ``off campus collaborative
programme''. As part of the partnership, Strides has launched a new
initiative called STEP (Strides Training and Education Plan) intend
to offer their employees an opportunity to acquire a MS in Pharma
Operations & Management while on the job.
- Enters into an agreement with Mayne Pharma Business Unit of
Australia based Mayne Group Ltd, to develop and manufacture a range
of six anti-infective products that Mayne will market and distribute
in the US and European markets.
-Strides Arcolab enters into an agreement for private placement
- Strides Arcolab signs License Agreement with KV Pharma for
exclusive marketing rights in the United States and Canada for 10 new
-Strides acquires sterile manufacturing facility in Poland
- Strides Arcolab has got tentative permission from the United
States Food and Drug Administration (USFDA) for Efavirenz tablets, an
anti-HIV drug. Efavirenz, is the generic version of Bristol Myers
Squibb's Sustiva, which helps in preventing the HIV virus from
- Strides Arcolab receives 2 more NDA approvals from US-FDA.
- Strides Arcolab Ltd on March 19, 2008 announced its third ANDA
approval for Fosphenytoin Injection 50mg/mL in 2 ml and 10 ml vials.
- Strides Arcolab Ltd has informed that Mr. V. S. Iyer has been
appointed as an Executive Director of the Company.
-Strides Arcolab Receives US FDA NOD To Commercialize First Sterlite
-Strides announces First European Approval for Oncology Product
-Strides Arcolab receives US FDA Nod to Commercialize First Liquid
-StridesArcoL Update on acquisition of outstanding minority
shareholding in Ascent Pharmahealth Limited
-Strides Arcolab joins the Malaysian Bio-xcell Ecosystem
-Strides Arcolab Announces US FDA approval for its 'Brazilian Sterile
-Strides Arcolab receives US FDA approval for Methotrexate Injection
-Strides Arcolab Announces Health Canada Approval For Tobramycin
-Strides Arcolab acquires Sterile Formulations facility to expand
core injectable biz
-Strides collaborates with Gilead Sciences
-Strides Arcolab receives ANDA approval from USFDA for Tenofovir
Disoproxil Fumarate and Emtricitabine Tablet.
- Strides Arcolab announces US FDA approval for its Italian
Semi-solids and Oinment facility.
- Strides announces WHO pre-qualification for Artemether +
-StelisBiopharma and Pieris Forge Alliance for Novel Anticalin
Therapeutics in Ophthalmology.
-Strides Arcolab - Re-branding Biotech Business as ''Stelis''.
-Strides Arcolab - Pfenex Inc. and Agila Biotech Private Ltd Announce
Joint Venture to Develop Biosimilar Products for the Global Market.
-- Medicines for Malaria Venture announces collaborations with Cipla
-Strides Arcolab makes strategic investment in Oncobiologics Inc.,
- Strides partners with Gilead Sciences Inc, to bring Hepatitis C
cure to 91 developing countries.
-Strides Arcolab receives US FDA approval for Buspirone Tablets.
-Strides Arcolab receives US FDA approval for Calcitriol Softgel.
-Strides Arcolab acquires 'Raricap' and India Branded Generic
Business of Bafna.
-Strides Arcolab to acquire Shasun Pharma in all stock deal.
-Strides Arcolab Ltd. has entered into an agreement with Fortuna
Public Relations Pvt. Ltd., Delhi appointing them as Company's Public
-Strides Arcolab Ltd that it has entered into a licensing agreement
with Gilead Sciences Inc,
-Strides Arcolab Ltd has launched the generic drug Sofosbuvir in
-Strides Arcolab gets USFDA nod for Polyethylene Glycol 3350
-Strides Arcolab gets USFDA nod for HIV treatment drug
-Strides Arcolab Ltd has approved the merger of Shasun
Pharmaceuticals Ltd with the company.
-Strides Arcolab has completed the Rs 1,910-crore acquisition of
Aspen Pharmacare, Australia.
-Strides Arcolab acquires CNS divisions of erstwhile Ranbaxy
-Strides Arcolab Ltd has changed from its present name Strides
Arcolab Limited to Strides Shasun Limited
-Strides Shasun updates on Acquisition of seven brands from Johnson
-Strides Shasun update on Acquisition of CNS divisions of erstwhile
-Strides Shasun to acquire a strategic stake in Generic Partners
-Strides Shasun to acquire controlling stake in Universal
-Strides Shasun receives USFDA Tentative Approval for Efavirenz
- Strides Shasun announces successful completion of US FDA inspection
at its Oral Dosage Facility in Bangalore.